Dordaviprone not checked

Jazz Pharmaceuticals · ONC201 · TIC10

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
1 active
8 in total · 2 in the EU
Targets
 

What this is

How it works
Protease Activator FDA class
How it’s given
“Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments”In the company’s words, NCT05580562 on ClinicalTrials.gov
Tested for
H3 K27M, Glioma
Main trialPhase 3
“This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.”In the company’s words, NCT05580562 on ClinicalTrials.gov
Other names
ONC201 · TIC10

Other drugs for Glioma

All 125 drugs for Glioma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2028 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Phase 2Terminated 31 Dec 2022 ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Phase 2Terminated 19 Jan 2023 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Phase 2Terminated 17 Apr 2023 Oral ONC201 in Adult Recurrent Glioblastoma
Phase 1/2Withdrawn Dec 2015 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Phase 1/2Terminated 17 Sep 2019 Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Phase 1Terminated 31 Dec 2022 ONC201 in Pediatric H3 K27M Gliomas
Phase 2Halted not given PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Dordaviprone

Following is part of Solo: you see every change to Dordaviprone the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in